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Evidence for altered cholesterol metabolism in Huntington's disease post
mortem brain tissue
Abstract
Aims Cholesterol plays an essential role in membrane structure and function, being especially important in
the brain. Alteration of brain cholesterol synthesis and metabolism has been demonstrated in several
Huntington's disease (HD) mouse and cell models; however, less is known about these alterations in human
tissue. This study aimed to identify alterations to cholesterol synthetic and metabolic pathways in human HD
brain tissue. Methods A broad range of cholesterol synthetic precursors, metabolites and oxidation products
were measured by gas chromatography-tandem mass spectrometry in five regions of human post mortem HD
brain and compared with age- and sex-matched control tissues. The level of enzymes that regulate cholesterol
homeostasis, cholesterol 24-hydroxylase and delta(24)-sterol reductase were investigated by Western blotting
and qPCR in putamen. Results The most significant changes were localized to the putamen, where a 60%
decrease in 24(S)-hydroxycholesterol, 30% increase in cholesterol and 100-200% increase in synthetic
precursors (lathosterol, zymosterol and desmosterol) was detected. The enzymes cholesterol 24-hydroxylase
and delta(24)-sterol reductase were also significantly decreased in HD putamen as compared with control
tissues. Free radical-generated cholesterol oxidation products 7-keto cholesterol and 7β-hydroxycholesterol
were also increased by 50-70% in HD putamen. Conclusion Human HD brain has significantly decreased
cholesterol metabolism and disrupted cholesterol homeostasis. Our data also indicate that lipid oxidative
stress accompanies HD pathology.
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Aims: Cholesterol plays an essential role in membrane structure and function, being 
especially important in the brain. Alteration of brain cholesterol synthesis and metabolism 
has been demonstrated in several Huntington’s disease (HD) mouse and cell models, however 
less is known about these alterations in human tissue. This study aimed to identify alterations 
to cholesterol synthetic and metabolic pathways in human HD brain tissue.  
Methods: A broad range of cholesterol synthetic precursors, metabolites and oxidation 
products were measured by GC-MS/MS in five regions of human post-mortem HD brain and 
compared to age- and sex-matched control tissues. The level of enzymes that regulate 
cholesterol homeostasis, cholesterol 24-hydroxylase and delta(24)-sterol reductase were 
investigated by Western blotting and qPCR in putamen.  
Results: The most significant changes were localised to the putamen, where a 60% decrease 
in 24(S)-hydroxycholesterol, 30% increase in cholesterol and 100 to 200% increase in 
synthetic precursors (lathosterol, zymosterol and desmosterol) was detected. The enzymes 
cholesterol 24-hydroxylase and delta(24)-sterol reductase were also significantly decreased in 
HD putamen as compared to control tissues. Free radical-generated cholesterol oxidation 
products 7-keto cholesterol and 7β-hydroxycholesterol were also increased by 50 to 70% in 
HD putamen. 
Conclusion: Human HD brain has significantly decreased cholesterol metabolism and 
disrupted cholesterol homeostasis. Our data also indicates that lipid oxidative stress 
accompanies HD pathology. 
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Abbreviations: 
HD = Huntington’ disease, GC-MS = gas chromatography-mass spectrometry, HTT = 
huntingtin, DHCR24 = delta(24)-sterol reductase, BBB = blood brain barrier, 24-OHC = 
24(S)-hydroxycholesterol, CYP46A1 = cholesterol 24-hydroxylase, 27-OHC = 27-
hydroxycholesterol, CYP27A1 = cholesterol 27-hydroxylase, CYP7B1 = 5-
hydroxycholesterol 7-α-hydroxylase, AD= Alzheimer’s disease, PD = Parkinson’s disease, 
ROS = reactive oxygen species, COPs = cholesterol oxidation products, 7β-OH = 7β-
hydroxycholesterol, 7-KC = 7-ketocholesterol, BDNF = brain derived neurotrophic factor.  
 
Introduction 
Huntington’s disease (HD) is an autosomal dominant, progressive neurodegenerative disease 
characterised by the expansion of a glutamine repeat on the N-terminus of the huntingtin 
protein (HTT). Classic symptoms include involuntary movement and cognitive dysfunction. 
The classical neuropathological hallmark of HD is the severe atrophy of the striatum (caudate 
and putamen) [1], with substantial volume loss in the order of 50%. While these brain regions 
are most severely affected, MRI techniques have highlighted that the hippocampus, cerebral 
cortex, globus pallidus and amygdala also have reduced volume in HD patients [2]. Loss of 
neurons is accompanied by progressive astrocytosis and an increased density of 
oligodendrocytes [3]. While it is not fully understood how the polyglutamine expansion 
causes cellular dysfunction in HD, it has been associated with lipids, altering membrane order 
[4] and the interaction with phospholipids [5].  Despite the genotypic identification of mutant 
huntingtin carriers, there is a lack of reliable biomarkers to predict HD progression or 
effectiveness of therapies. Several studies have identified that cholesterol synthesis and 
metabolism in HD cell lines and animal models is significantly disturbed [6-8], but the 
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mechanisms and metabolic pathways affected have not been fully examined in human HD 
brain. 
 
Cholesterol is highly concentrated in the brain, accounting for 25% of total body cholesterol. 
The majority of cholesterol is found in myelin, accounting for 70% of total cholesterol, with 
the remainder found in cellular membranes of neurons and glial cells. Cholesterol has an 
essential role in many neurological processes including synaptogenesis [9], axon growth [10] 
and maintenance of dendrites [11]. Structurally, cholesterol modulates membrane fluidity and 
organisation [12] where it can alter signalling functions, membrane protein organisation and 
lipid raft structure [13-16]. Brain levels of cholesterol are tightly regulated by de novo 
synthesis, a pathway that involves over 20 steps. In the late stage of cholesterol synthesis the 
pathway branches at lanosterol into the Bloch pathway via the precursor desmosterol, or the 
Kandutsch-Russell pathway via lathosterol. Several other post squalene precursors exist in 
these pathways (see Fig. 1). Plasma levels of synthetic precursors have been positively 
correlated to whole body cholesterol synthesis [17, 18], but this does not reflect cholesterol 
synthesis in the central nervous system. Direct measurement of precursor levels in brain 
tissue is therefore necessary to monitor the cholesterol synthetic pathway [7, 8, 19]. Defects 
in the cholesterol synthetic pathway can have severe consequences, especially in the brain 
where tight regulation of cholesterol synthesis is essential for normal neuronal function. 
Mutations in downstream synthetic enzymes such as delta(24)-sterol reductase (DHCR24) 
can cause desmosterolosis [20], a severe developmental and neurological disorder.  
The blood brain barrier (BBB) is impermeable to cholesterol, preventing fluctuations in 
circulating cholesterol affecting brain levels. The hydroxylation of cholesterol to more polar 
oxysterols enables movement across the BBB. 24(S)-Hydroxycholesterol (24-OHC), formed 
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by the brain specific enzyme cholesterol 24-hydroxylase (CYP46A1) has been identified as 
the major route of cholesterol elimination from the human brain [21]. Since CYP46A1 
expression is primarily localised to neurons [22], it has been suggested that generation of 24-
OHC (as measured in plasma) is a marker of metabolically active neurons in the brain [23]. 
Plasma 24-OHC levels are reduced in HD patients [24, 25] and recent evidence suggests that 
changes in CYP46A1 and 24-OHC brain levels may play a role in neurodegeneration [26-29]. 
However, the exact role this might play in HD pathogenesis has not been established. 
Oxysterols formed in peripheral tissue may also enter the brain. C27 hydroxylation of 
cholesterol forms 27-hydroxycholesterol (27-OHC), an enzymatic reaction that occurs in 
many tissues outside the central nervous system. A concentration gradient results in a net 
movement of 27-OHC from circulation into the brain [30], where it is quickly metabolised 
into more polar products (including dihydroxysterols and cholestenoic acids), catalysed by 
the enzymes cholesterol 27-hydroxylase (CYP27A1) and 5-hydroxycholesterol 7-α-
hydroxylase (CYP7B1) [31]. Accumulation of 27-OHC has been described in cases of 
Alzheimer’s disease (AD) [32] as well as patients with hereditary defects in the CYP7B1 gene 
[33], but very little is known regarding 27-OHC changes in HD. 
Accumulation of unrepaired oxidative damage to biological macro molecules is a major 
component of neurodegenerative diseases, including AD [34] and Parkinson’s disease (PD) 
[35]. Oxidative stress is also observed in HD with markers of lipid peroxidation and DNA 
oxidation elevated [36-38]. Brain lipids represent a major target for oxidation, particularly 
cell membrane cholesterol that is susceptible to reactive oxygen species (ROS) attack and 
formation of cholesterol oxidation products (COPs). 7β-Hydroxycholesterol (7β-OHC) and 7-
ketocholesterol (7-KC) are formed by direct ROS attack at the 5,6 double bond on 
cholesterol, and are elevated in diseases and pathological models that involve oxidative stress 
including atherosclerosis [39, 40], cystic fibrosis [41] and retinal photodamage [42]. Due to 
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the large pool of cholesterol in the brain, COPs represent potentially important biomarkers for 
neurodegenerative diseases. 
Perturbed cholesterol pathways have been previously reported in HD mouse and cell models 
[6, 7, 19, 43]. While these models have described significant alteration of cholesterol 
synthesis and metabolism, the current literature contains very limited data obtained from 
human tissue, which is required for greater understanding of human HD pathophysiology. 
Here we report for the first time the level of cholesterol metabolites, synthetic precursors and 
oxidation products in 13 cases of human HD across 5 brain regions. We have also 




Materials and Methods 
Materials 
Desmosterol-d6, zymosterol-d5, zymosterol and lanosterol-d6 were obtained from Avanti 
lipids (Alabaster, AL, USA). Tert- butylhydroxytoluene (BHT), cholesterol, -cholestane, 
7–hydroxycholesterol, 7-dehydrocholesterol and 7-ketocholesterol and squalene were from 
Sigma (St. Louis, MO, USA). Lathosterol, lanosterol, desmosterol, 27-hydroxycholesterol, 
campesterol, and were obtained from Steraloids (Newport, RI, USA). Campesterol-d3, 7–
hydroxycholesterol-d7, lathosterol-d4 and 7-ketocholesterol-d7 were purchased from CDN 
Isotopes (Quebec, Canada). 27-hydroxycholesterol-d5, 24-hydroxycholesterol and 24-
hydroxycholestero-d7 were from Medical Isotopes , Inc (Pelham, AL, USA). Squalene-d6 and 
24,25-dihydrolanosterol-d6 was obtained from Toronto research chemicals (TRC, Ontario, 
Canada). All standards obtained were of the highest purity (>95%). Methanol, hexane, 
methyl tert-butyl ether (MTBE), acetonitrile, toluene, formic acid and NaOH were purchased 
from Ajax Finechem (Thermo Fisher Scientific, AU). CUQAX223 UCT Clean-Up QAX2 
solid phase extraction columns and BSTFA (N,O-bis(trimethylsilyl) trifluoroacetamide) + 
1% TMCS  (trimethylchlorosilane) was purchased from PM Separations (Qld, Australia). 
 
Human brain tissue 
Frozen brain tissues from five brain regions (putamen, caudate, cerebellum, grey and white 
frontal cortex) were received from the Victorian Brain Bank Network. The cohort contained 
13 cases of HD and 13 controls from each brain region. Tissue was transported on dry ice and 
stored at -80°C until analysis. Demographic and basic clinical data are presented in Table 1. 
The mean age of control cases was 68.9 ± 1.9 y which was not significantly different from 
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the HD cases with mean age of 67.3 ± 2.2 y. Post mortem interval (PMI) of control cases 
(41.5 ± 4 h) and tissue pH (6.4 ± 0.1) was not significantly different to HD PMI (37.5 ± 6.2 
h) or tissue pH (6.4 ± 0.04). All brain tissue was from the left hemisphere of Caucasian 
donors. Ethics approval was from the University of Wollongong Human Research Ethics 
Committee (HE10/327). Control tissue was screened using standardized protocols to confirm 
the absence of degenerative pathologies. The research was carried out in accordance with the 
Declaration of Helsinki (2008) of the World Medical Association. All persons gave their 
informed consent prior to their inclusion in the study. 
 
Lipid extraction 
Brain lipids were extracted as previously described with minor modifications [44]. Frozen 
brain tissue (~5-10 mg) was weighed directly into a 0.5 mL polypropylene tube containing 5 
Zircosil® ceramic beads (1.3 mm) (Klausen Pty Ltd, NSW, Australia), 150 µL methanol 
(0.01% BHT) and internal standards (4oC). Tissue was homogenised at 4°C using a Precellys 
24 homogeniser (Bertin Technologies) (2 x 20 s at 5,000 rpm) and the homogenate was 
transferred to a clean glass vial. The tube and ceramic beads were washed with 100 µL 
methanol (4°C) and was added to the homogenate with 250 µL of NaOH (1 M). The sample 
was hydrolysed at room temperature for 16 h in the absence of light and then acidified with 
330 µL of 1 M formic acid. The sample was made up to a final volume of 3 mL (8% 
methanol, pH 4.5) by the addition of 2.2 mL milliQ water. Solid-phase extraction (SPE) was 
carried out on a 200 mg mixed C8/anion exchange quaternary amine column (CUQAX223, 
UCT Inc.) that had been preconditioned with 2 mL methanol and then 2 mL 40 mM formic 
acid buffer (pH 4.5). The lipid extract was loaded and the column washed with 2 mL 
methanol in 40 mM formic acid (40:60). The SPE column was dried with N2 gas flow for 5 
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min. Sterols and oxysterols were eluted with 2 mL hexane followed by 2 mL hexane/MTBE 
(50:50).  
 
GC-MS sterol analysis 
GC-MS sterol analysis was performed as previously described with minor modifications [35]. 
The sterol/oxysterol fraction was dried under N2 at 37°C and derivatised by the addition of 20 
µL acetonitrile and 20 µL BSTFA + 1% TMCS  for one hour at 37oC. Samples were dried 
under N2 and immediately reconstituted in 40 µL toluene for GC-MS/MS analysis. Selective 
reaction monitoring (SRM) analysis of sterols/oxysterols was carried out on an Agilent 
7000B triple quadrupole mass selective detector interfaced with an Agilent 7890A GC system 
gas chromatograph. Quantification was performed by Agilent Masshunter Quantitative 
software (V B.05.00) by comparison of specific SRM transitions with their heavy isotopes 
and using relative response factor (RRF) calibration. Cholesterol was quantified using the 
internal standard α-cholestane in a separate injection and chromatographic run.  
 
Western Blotting 
Brain tissue (~20 mg) was added to 250 uL ice cold radio-immunoprecipitation assay (RIPA; 
50 mM Tris, 150 nM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% Triton X 100) buffer 
containing 1% protease inhibitor (P8340, Sigma) and homogenised at 4°C using a Precellys 
24 homogeniser (Bertin Technologies) (2 x 20 s, 6000 rpm). The homogenate was 
centrifuged at 14 000 x g and the soluble fraction taken for SDS-PAGE. Homogenates were 
incubated at 95°C for 10 min with loading dye containing β-mercaptoethanol. Equal amounts 
of protein (90 µg) were loaded onto a 12% acrylamide gel and electrophoresed for 1 h at 
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150V. Proteins were then transferred onto a 0.4 µm nitrocellulose membrane (BIO-RAD, 
Gladesville, NSW, Australia) for 35 min at 100V. Antigen retrieval was performed by adding 
50 mL of boiling phosphate buffered saline + tween 20 (PBST) to the membrane and left to 
cool to room temperature. The membrane was blocked with a 10 mL solution of PBST 
containing 5% skim milk powder, rocking for 1 h at room temperature. Membranes were 
probed with antibodies detecting CYP46A1 1:100 (1F11, Santa Cruz Biotechnology) and 
DHCR24 1:1000 (ab137845, Abcam). Antibodies were diluted in 10 mL PBST 5% skim milk 
powder and incubated with membranes overnight, rocking at 4°C. Membranes were washed 3 
x 10 min with PBST at room temperature before being incubated for 1 h at room temperature 
with a species specific IgG-HRP conjugated secondary antibody (1:3000). Membranes were 
washed 3 x 10 min with PBST before chemiluminescent detection of signal. Membranes were 
stripped, washed and re-probe for β-actin (1:10 000) following the protocol outlined above. 
Signal intensity was quantified using ImageJ software V1.46r (National Institutes of Health, 
USA), and normalised for β-actin. 
 
qPCR 
The quantitative PCR of human brain tissue was performed as previously described [45] with 
minor modifications. Briefly, human tissue (~30mg) was added to 10 volumes of TRIzol 
reagent (wt:vol) and homogenised in a Precellys 24 homogeniser at 2 x 20 s at 5500 rpm. The 
RNA concentration and purity was determined spectrophotometrically with a Nanodrop 1000 
(Thermo Scientific). Following the manufacturer’s protocol, 2 µg of total RNA was used to 
synthesise cDNA using a Tetro cDNA synthesis kit (Oligo dT18) (Bioline, Sydney, Australia). 
Quantitative PCR was performed using a Roche Lightcycler 480 using SensiFAST SYBR 
No-ROX kit (Bioline) following the manufacturer’s instructions. Analyses were carried out in 
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triplicate and gene of interest mRNA was normalised to GAPDH and U6 mRNA levels. Gene 
expression was calculated using the comparative threshold cycle (Ct) value method using the 
formula 2-ΔΔCt (ΔΔCt = ΔCt sample – ΔCt reference) as described [46]. All primers were 
purchased from Sigma Aldrich (Sydney, Australia). The primer sequences used are as 
follows: CYP46A1 (F: TTCTAGGACACCTCCCCTGC and R: 
CAGGTCCATACTTCTTAGCCCAAT) DHCR24 (F: TGTTCGTGTGCCTCTTCCTC and 
R: ATTCCCGCACCTGCTTCTG) GAPDH (F: GAGCACAAGAGGAAGAGAGAGACCC 
and R: GTTGAGCACAGGGTACTTTATTGATGGTACATG) U6 (F: 
CTCGCTTCGGCAGCACA and R: AACGCTTCACGAATTTGCGT). 
 
Statistical analysis  
Statistical analyses were performed using GraphPad Prism software V5.00 (Graphpad 
Software Inc., USA). An unpaired t-test was used to test for significantly different means, an 
F-test was used to determine if variances were significantly different. Welch’s correction for 
unequal variances was used when variances were found to be significantly different. 
Additional post hoc adjustments for multiple comparisons were conducted using the 
Benjamini and Hochberg method [47] in JMP software V12.1.0 (SAS Institute Inc., USA). 
All results are expressed as mean ± SEM with an adjusted P < 0.05 considered significant. A 
full list of P-values and adjusted P-values can be found in Supplemental Table 1. 
 
Results 
Human HD post mortem brain tissue from putamen, caudate, frontal cortex (grey and white) 
and cerebellum was analysed using mass dilution GC-MS/MS. Cholesterol metabolites, 
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oxidation products and synthetic precursors are presented as percent relative change 
compared to control (Fig. 2). Absolute values of sterols measured are provided in 
Supplemental Table 2. 
 
Cholesterol metabolites 
The most significant changes were detected in HD putamen, a region that is severely affected 
in HD. The brain specific cholesterol metabolite 24-OHC, was reduced close to 3-fold (p = 
0.0011) in HD putamen (Fig. 2A). Caudate was the only other region to show changes in this 
metabolite with a 3-fold reduction (p = 0.0099) of 24-OHC in HD tissue compared to control 
tissue (Fig. 2A). 27-OHC, a peripheral cholesterol metabolite was significantly increased by 
3-fold in HD putamen (p = 0.0196). 
Cholesterol oxidation products 
HD putamen was the only brain region to show evidence of oxidative stress, with a 50 to 70% 
increase in the cholesterol oxidation products 7-KC (p = 0.00495) and 7β-OH (p = 0.0355) 
(Fig. 2B). 
 
Cholesterol synthetic precursors 
Altered cholesterol synthesis was evident in HD putamen which exhibited increases in the 
cholesterol synthetic precursors, desmosterol (3-fold, p = 0.0140), lathosterol (2-fold, p = 
0.0495), zymosterol (3-fold, p = 0.0145) and 24, 25 dihydro lanosterol (2-fold, p = 0.0140) 
(Fig 2C). Total cholesterol levels were also significantly increased by 30% in HD putamen (p 
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= 0.0470) (Fig. 2D). No other brain regions were found to have significant changes in 
cholesterol precursors, or cholesterol levels. 
 
Metabolic and synthetic enzymes 
To further investigate pathways that may contribute to changes in brain cholesterol 
metabolism and synthesis observed in putamen, we examined two major enzymes involved 
by western blotting. The protein level of CYP46A1 in HD was reduced 10-fold compared to 
control (p = 0.0027) (Fig. 3A). We also detected a significant (10-fold) reduction (p = 
0.0014) of DHCR24 protein levels (Fig. 3B), which is in agreement with the accumulation of 
desmosterol seen in HD putamen (Fig. 2B). 
The mRNA levels of the genes coding for cholesterol 24-hydroxylase (CYP46A1) and 
delta(24)-sterol reductase (DHCR24) were also measured in putamen using quantitative PCR. 
mRNA levels did not reflect protein levels and were not significantly changed between HD 
and control tissue in both CYP46A1 and DHCR2 (Fig. 4). mRNA levels normalised to 
individual house keeper genes can be found in Supplemental Figure 1. 
Discussion 
Alteration of cholesterol metabolism has been recently linked to several neurodegenerative 
diseases including AD, PD and HD [35, 43, 48]. In particular, the elimination pathway where 
24-OHC is formed by the hydroxylation of cholesterol has been suggested as a contributing 
factor in neurodegeneration [49]. Neuronal 24-OHC has a major role in the turn-over of 
cholesterol in the brain [21], and the level of 24-OHC in plasma has been suggested as a 
measure of CYP46A1 enzymatic activity and thus metabolically active neurons [23].  
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Previous studies have found that the plasma levels of 24-OHC in HD patients correlate with 
disease severity and brain volume measured by MRI [24, 25]. Here for the first time we 
report the levels of 24-OHC in human HD post-mortem brain tissue. A significant reduction 
of 24-OHC was found in HD putamen along with a large (10-fold) reduction in the protein 
level of CYP46A1, the enzyme responsible for 24-OHC formation. Reduced enzyme levels 
may be due to neuronal loss, the location which CYP46A1 is primarily located. Alterations in 
post-transcriptional regulation may also play a role since no change in mRNA expression was 
detected between control and HD. This is potentially relevant as protein turnover is known to 
be dysregulated in HD cell models [50]. Caudate (another striatal region affected in HD) also 
had reduced levels of 24-OHC, while grey and white frontal cortex and cerebellum showed 
no change. Although the cerebral cortex is affected in later stages of HD [2, 51], the degree of 
volume loss and astrocytosis is substantially less compared to the striatum [2, 52, 53]. 
Reduced 24-OHC levels in HD striatum supports previous human studies that reported 
reduced plasma levels of this metabolite in HD patients [24, 25]. Our data indicates that 
decreased circulating 24-OHC levels are likely the result of reduced 24-OHC production in 
affected regions and not an aberration of BBB 24-OHC flux. In the mature brain, delivery of 
cholesterol synthesised in the astrocyte is required for normal neuronal function [9, 10, 54].  
It has been hypothesised that 24-OHC production in neurons acts as a feedback molecule to 
initiate the delivery of cholesterol from astrocytes to neurons therefore maintaining 
homeostasis [55]. There is also evidence to suggest that CYP46A1 may have neuroprotective 
properties, being upregulated near plaques [27] and in glia of human AD brain [56]. Whether 
reduced levels of CYP46A1 in HD is a secondary event reflecting active neuron loss, or is a 
pathogenic factor altering cholesterol metabolism and synthesis remains to be established. 
A defect in cholesterol synthesis has been previously described in several cell and mouse 
models of HD. Specifically; a reduction in the cholesterol synthetic precursors lathosterol and 
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lanosterol as well as cholesterol in the YAC128 mouse [19], reduced levels of lathosterol and 
lanosterol but not cholesterol in the R6/2 mouse model [7], reduced mRNA levels of 
cholesterol synthetic enzymes in R6/2 mouse and human HD fibroblasts [6] and reduced 
cholesterol synthetic enzymes in a transgenic HD cell model [43]. In contrast to these 
findings, our data in end stage human HD putamen describes an increase in cholesterol 
synthetic precursors from both the Bloch (desmosterol and 24,25 diHydro lanosterol) and 
Kandutsch-Russell (lathosterol and zymosterol) pathways and an increase in total cholesterol 
levels. No significant changes in squalene levels were observed (Suppl. Table 2) suggesting 
that the earlier mevalonate pathway did not influence the changes that we measured later in 
the pathway. The increase in cholesterol and synthetic precursors was only observed in the 
putamen; a region that degenerates early and severely in the human disease [57]. In contrast 
to macro and microscopic classification of disease pathology which sees the caudate 
degenerate consistently with the putamen [53, 57], we did not observe any cholesterol 
synthetic alterations in this region.  While the cholesterol synthetic changes observed in the 
putamen may suggest an overall increase of cholesterol synthesis utilising both pathways, we 
believe this is not the case for the Bloch pathway. In our study, HD putamen had significantly 
higher levels of desmosterol, an immediate synthetic precursor of cholesterol and a substrate 
of DHCR24. Significantly depleted protein levels of DHCR24 in human HD putamen (10-
fold) provides convincing evidence to explain the reduced DHCR24 activity and subsequent 
accumulation of desmosterol. Unaltered mRNA levels of DHCR24 in putamen again suggests 
enzyme levels are being affected post-transcription. Previous in vitro examination of 
cholesterol synthesis in specific cell types found astrocytes utilise the Bloch pathway via 
desmosterol, while neurons primarily utilised 7-dehydro cholesterol and other precursors 
from the Kandutsch-Russell pathway [58]. This suggests that in late stage human HD, 
desmosterol accumulates in astrocytes due to down regulated DHCR24. An increased density 
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of oligodendrocytes and activated astrocytes is known to be present in HD [3] and is believed 
to be a compensatory response to demyelination in HD [59]. While the specific cell type/s 
exhibiting elevated Kandutsch-Russell synthetic precursors is yet to be determined, increased 
oligodendrocytes attempting remyelination in affected tissue may contribute to this.  
 
Previous studies in HD mouse brain reported a significant reduction of the cholesterol 
precursor lathosterol, which is found in the Kandutsch-Russell pathway. In contrast, the 
Bloch pathway precursor desmosterol, was either unchanged [19] or not reported [7] in these 
previous HD mouse studies. Examining precursors from both arms of the cholesterol 
synthetic pathway in these mouse models enables greater insight into the alterations occurring 
in different cell types, and their possible response to HD pathology / neurodegeneration. The 
differences seen between HD mouse models, in vitro cell models, and human post-mortem 
tissue may reflect a difference in the homeostatic response to mutant HTT between organisms 
and cell types. The differences in the data derived from our current study and previous mouse 
models and cell culture models may also reflect that in this study we examined end stage HD 
where a significant number of vulnerable neurons are predicted to have been lost. Examining 
earlier stages of the disease in brain tissue is therefore important to consolidate the role of 
cholesterol synthesis and metabolism in the early stages of HD in humans. 
 
27-Hydroxycholesterol, a metabolite of cholesterol that is produced predominantly in 
peripheral tissue, was increased in the putamen of human HD brain as compared to controls. 
A trending increase was observed in grey cortex and cerebellum; however this lost 
significance after P-value adjustment. While an increased flux of 27-OHC into the brain may 
be caused by a disrupted BBB, we believe this is not the case in this tissue since sterols that 
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are present in higher peripheral abundance such as campesterol (a dietary derived 
phytosterol) were not significantly different between HD and control brain tissues (data not 
shown). As there is a net movement of 27-OHC from circulation into the brain [30], 27-OHC 
accumulation may be the result of a decrease in the activity of enzymes (such as CYP27A1) 
that further metabolises this oxysterol to cholestenoic acids [31]. Accumulation of 27-OHC is 
potentially important in neurodegeneration as in vitro studies have shown 27-OHC promotes 
β-amyloidogenesis [60] as well as being elevated in human AD brain and transgenic mice 
[32, 61]. While there is little direct in vivo physiological evidence that cholesterol metabolites 
promote neuronal damage, further studies are required to investigate the hypothesis that 
preventing the accumulation of 27-OHC in the brain reduces neurodegeneration in AD and 
HD. 
 
Along with measuring cholesterol metabolites and precursors, our GC-MS method was able 
to sensitively detect oxidation products of cholesterol, and use these as markers of oxidative 
stress in HD brain tissue. Oxidative stress has been previously shown in HD [36], and in 
several other neurodegenerative diseases [34, 35, 62]. Similar to changes seen in other 
sterols, significant increases in 7-KC and 7β-OH were only observed in putamen. The 
specific increase in oxidation products in the putamen is consistent with this region being 
affected early and severely in HD [57]. 7-KC and 7β-OH have been shown to be stable, and 
previously used as markers of oxidative stress in plasma [40] and CSF [63]. Measurement of 
cholesterol oxidation in HD plasma together with other sterols may represent a convenient 
tool to follow progression, quantify severity, and assess therapeutic effectiveness in patients. 
Importantly, these markers can be measured sensitively and reliably by GC-MS techniques. 
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Homeostasis of cholesterol is essential for neurological function however the precise role of 
cholesterol in HD neurodegeneration is still debated. Evidence suggests that cholesterol 
accumulation in HD alters membrane organisation and cell signalling, enhancing the 
susceptibility of striatal neurons to excitotoxicity [4]. Another hypothesis suggests that 
impaired cholesterol synthesis drives neurodegeneration by limiting the supply of cholesterol 
to neurons [19]. As a result synaptogenesis and dendrite outgrowth is impaired [9, 11], and 
neurotransmission is disrupted [64]. It is also believed that a reduction of brain derived 
neurotrophic factor (BDNF) in HD [65] may play a significant role in neurodegeneration 
[66]. BDNF is a neurotrophin expressed by neurons which promotes cell survival, 
differentiation and growth [67]. Among these properties, BDNF has been shown to promote 
DHCR24 expression [68]. Therefore, a loss of BDNF action may also contribute to the 
cholesterol homeostatic imbalance we have detected in HD putamen. 
Our study identifies for the first time that several cholesterol synthetic and metabolic 
pathways are disturbed in multiple brain regions of human HD, particularly putamen which 
plays a central role in HD pathophysiology. These data provide evidence to support previous 
studies that link altered cholesterol synthesis, metabolism and oxidative stress with the 
neuropathological process involved in HD. Since HD shares similar sterol disturbances as 
other late-onset neurodegenerative diseases, we believe these changes represent potential 
biomarkers for neurodegenerative disease and elucidating cholesterol related mechanisms of 
neuropathology may provide targets for therapeutic intervention. The key finding of reduced 
CYP46A1 in human HD brain confirms previous studies in HD patient plasma that indicate 
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Fig. 1 Simplified pathway showing cholesterol synthesis, metabolism and free radical 
oxidation relevant to this study. Major post squalene cholesterol synthetic precursors shown 
follow a branched pathway, the Kandutsch-Russell pathway or Bloch pathway. Cholesterol 
can be oxidised enzymatically to form 24(S)-hydroxycholesterol (24-OHC) or 27-
hydroxycholesterol (27-OHC) by cholesterol 24-hydroxylase (CYP46A1) and cholesterol 27-
hydroxylase (CYP27A1). Reactive oxygen species (ROS) can oxidise cholesterol to form 7-
ketocholesterol and 7β-hydroxycholesterol. The position of delta(24)-sterol reductase 
(DHCR24), a cholesterol synthetic enzyme is also shown. Broken lines indicate intermediates 
that have not been shown in this simplified scheme 
Fig. 2 Sterol levels in human HD putamen, caudate, grey cortex, white cortex and 
cerebellum. (A) Cholesterol metabolites (B) Cholesterol oxidation products (C) Cholesterol 
synthetic precursors (D) Cholesterol were measured by GC-MS/MS.  Levels are expressed as 
a percentage change against control tissue. n = 12-13 per group, error bars represent +SEM 
**p < 0.005, *p < 0.05 
Fig. 3 Protein level of cholesterol synthetic and metabolic enzymes in human putamen. Brain 
tissue homogenates from HD and control were probed for (A) cholesterol 24-hydroxylase 
(CYP46A1) and (B) delta(24)-sterol reductase (DHCR24) by western blotting. 
Representative blots are shown (n = 3 per group). Integrated optical density for all blots (n = 
9 per group) is represented as relative abundance compared to control (assigned a value of 
1.0). Blots were normalised to β-actin level. Error bars represent +SEM. **p < 0.005 
Fig. 4 mRNA levels of genes coding for cholesterol synthetic and metabolic enzymes in 
human putamen. The level of CYP46A1 (coding for cholesterol 24-hydroxylase) and 
DHCR24 (coding for delta(24)-sterol reductase) in brain tissue was determined by qPCR (n = 
  25
9 for control and HD). The genes of interest were normalised to GAPDH and U6 mRNA 
levels and expressed relative to control (assigned a value of 1.0). Error bars represent +SEM 
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